Reaction
Chronic Inflammatory Demyelinating Polyradiculoneuropathy reporting signals
As of the last recalculation, Chronic Inflammatory Demyelinating Polyradiculoneuropathy appears in 1,400 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is HUMAN IMMUNOGLOBULIN G (PRR 98.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Human Immunoglobulin G | 125 | 98.8 | 99.4 |
| Brentuximab Vedotin | 18 | 26.4 | 26.5 |
| Busulfan | 23 | 22.1 | 22.1 |
| Fludarabine Phosphate | 32 | 12.4 | 12.4 |
| Adalimumab-Fkjp | 37 | 12.2 | 12.2 |
| Adalimumab-Aaty | 37 | 11.9 | 11.9 |
| Adalimumab-Adaz | 39 | 11.3 | 11.3 |
| Mycophenilic Acid | 15 | 10.9 | 10.9 |
| Tizanidine Hydrochloride | 13 | 10.8 | 10.8 |
| Entecavir | 8 | 10.2 | 10.2 |
| Zoledronic Acid | 23 | 8.6 | 8.6 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 4 | 6.9 | 6.9 |
| Vilazodone Hydrochloride | 4 | 6.5 | 6.5 |
| Pemetrexed | 9 | 6.3 | 6.3 |
| Bortezomib | 34 | 5.8 | 5.8 |
| Ipilimumab | 16 | 5.6 | 5.6 |
| Pembrolizumab | 37 | 5.3 | 5.3 |
| Nivolumab | 30 | 4.7 | 4.7 |
| Diroximel Fumarate | 3 | 3.7 | 3.7 |
| Rimegepant Sulfate | 3 | 3.5 | 3.5 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 4 | 1.9 | 1.9 |